Hemp Company Challenges DEA Position That Synthetic HHC Is Already Illegal

Bluestar Operations told the Fourth Circuit that DEA cannot label its HHC drug-code rule both consequential enough to publish and too technical to challenge, and argued that current hemp law covers hemp-derived HHC. Oklahoma hemp manufacturers should continue treating synthetic-cannabinoid production as a high-risk federal compliance area while the court weighs DEA’s standing and scheduling arguments.